Source:
by | Jan 30, 2018 | 0 Comments
Military
Source:
Source:
Source:
Sanofi, Facing Threat From Generics, Moves to Buy Hemophilia Drug Maker
The $11.6 billion deal for Bioverativ would bolster the French pharmaceutical giant’s portfolio as it faces falling sales for its diabetes drug, Lantus. Source: https://www.nytimes.com/2018/01/22/business/dealbook/sanofi-hemophilia-bioverativ.html?partner=rss
Recent Comments